Who are Atelerix Life Sciences's investors?

Atelerix Life Sciences's investors include CWRU Technology Ventures.

How much funding has Atelerix Life Sciences raised?

Atelerix Life Sciences has disclosed $650K raised across 1 round.

Where is Atelerix Life Sciences headquartered?

Atelerix Life Sciences is headquartered in Indianapolis, US.

Atelerix Life Sciences

Indianapolis, US · Founded 2020 · Delaware corporation · 1 known investors

Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats. The company is advancing pre-clinical and clinical-stage drug candidates, with ATLX-0199 as its lead compound designed to stimulate respiratory drive while preserving pain relief and sedation.

Biotech Healthtech Medical Devices

Founders & leadership

David KalergisNamed on SEC filing

William AkridgeNamed on SEC filing

Board

Peter Barton HuttBoard director

Investors · 1

CWRU Technology VenturesCleveland · $50K – $250K

Reported raises · per SEC filings

Form D private placements

$650K disclosed across 1 round · 2022

▶$650KraisedOct 2022 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David KalergisExecutive Officer, Director, Promoter
William AkridgeDirector
Peter Barton HuttDirector

Offering amount: $3.5M
Amount sold: $650K
First sale: Sep 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Exelixis6 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Aro Biotherapeutics5 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies competing with Atelerix Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2022	$1.8M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Atelerix Life Sciences do?: Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats. The company is advancing pre-clinical and clinical-stage drug candidates, with ATLX-0199 as its lead compound designed to stimulate respiratory drive while preserving pain relief and sedation.
Who are Atelerix Life Sciences's investors?: Atelerix Life Sciences's investors include CWRU Technology Ventures.
How much funding has Atelerix Life Sciences raised?: Atelerix Life Sciences has disclosed $650K raised across 1 round.
Where is Atelerix Life Sciences headquartered?: Atelerix Life Sciences is headquartered in Indianapolis, US.